ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
June 12, 2019Cost per QALY, or quality-adjusted life year, measures the economic value of a health care intervention; the lower the cost per QALY, the higher the value of the treatment. -
FDA delays review of peanut allergy drug amid Trump shutdown
January 17, 2019One of the first pharma victims of the current partial shutdown of the US government has emerged after the FDA said it would delay a review of a peanut allergy drug from Aimmune Therapeutics. -
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
December 24, 2018Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has submitted a ....
Pharma Sources Insight January 2025
